↓ Skip to main content

Checkpoint inhibitors in hematological malignancies

Overview of attention for article published in Journal of Hematology & Oncology, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 523)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
8 news outlets
twitter
2 tweeters

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Checkpoint inhibitors in hematological malignancies
Published in
Journal of Hematology & Oncology, May 2017
DOI 10.1186/s13045-017-0474-3
Pubmed ID
Authors

Chi Young Ok, Ken H. Young

Abstract

Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to escape immune surveillance. Accumulating data support that their functions are dysregulated in lymphoid neoplasms, including plasma cell myeloma, myelodysplastic syndrome, and acute myeloid leukemia. In lymphoid neoplasms, aberrations in 9p24.1 (PD-L1, PD-L2, and JAK2 locus), latent Epstein-Barr virus infection, PD-L1 3'-untranslated region disruption, and constitutive JAK-STAT pathway are known mechanisms to induce PD-L1 expression in lymphoma cells. Clinical trials demonstrated that PD-1 blockade is an attractive way to restore host's immune function in hematological malignancies, particularly classical Hodgkin lymphoma. Numerous clinical trials exploring PD-1 blockade as a single therapy or in combination with other immune checkpoint inhibitors in patients with hematologic cancers are under way. Although impressive clinical response is observed with immune checkpoint inhibitors in patients with certain cancers, not all patients respond to immune checkpoint inhibitors. Therefore, to identify best candidates who would have excellent response to checkpoint inhibitors is of utmost importance. Several possible biomarkers are available, but consensus has not been made and pursuit to discover the best biomarker is ongoing.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 <1%
Unknown 104 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 18%
Researcher 18 17%
Student > Master 17 16%
Other 14 13%
Student > Bachelor 11 10%
Other 23 22%
Unknown 3 3%
Readers by discipline Count As %
Medicine and Dentistry 42 40%
Biochemistry, Genetics and Molecular Biology 17 16%
Agricultural and Biological Sciences 17 16%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Immunology and Microbiology 5 5%
Other 9 9%
Unknown 10 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 62. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2017.
All research outputs
#223,679
of 12,114,099 outputs
Outputs from Journal of Hematology & Oncology
#2
of 523 outputs
Outputs of similar age
#10,841
of 268,700 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 23 outputs
Altmetric has tracked 12,114,099 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 523 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,700 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.